Physician profile
Bomee Kim
NPI 1114467172
$1,012.49
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $121 · 2021: $614 · 2022: $13.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $248.59 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $216.32 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $128.00 | 2021 | |
| Aerie Pharmaceuticals, INC. | $106.82 | 2021 | |
| Heidelberg Engineering, INC. | $105.63 | 2021 | |
| Optos, INC. | $93.66 | 2020 | |
| Glaukos Corporation | $43.40 | 2019 | |
| Allergan, INC. | $30.84 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $24.15 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $15.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bomee Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.